Literature DB >> 27012365

Real-Time GFP Intravital Imaging of the Differences in Cellular and Angiogenic Behavior of Subcutaneous and Orthotopic Nude-Mouse Models of Human PC-3 Prostate Cancer.

Yong Zhang1, Makoto Toneri1,2, Huaiyu Ma1, Zhijian Yang1, Michael Bouvet2, Yusuke Goto3, Naohiko Seki4, Robert M Hoffman5,6.   

Abstract

There are two major types of mouse xenograft models of cancer: subcutaneous implantation and orthotopic implantation. Subcutaneous transplant models are widely used with both cancer cell lines and human-tumor specimens. Recently, subcutaneous models of patient tumors, termed patient-derived xenographs (PDX) have become highly popular and have acquired such names as "Avatar" and "Xenopatients." However, such s.c. models rarely metastasize and are therefore not patient-like. In contrast, orthotopic models have the capability to metastasize. If intact fragments of tumor tissue are implanted by surgical orthotopic implantation (SOI), the metastatic potential can match that of the donor patient. The present study images in real time, using green fluorescent protein (GFP) expression, the very different tumor behavior at the orthotopic and subcutaneous sites of human prostate cancer PC-3 in athymic nude mice. By day-2 after tumor implantation, the orthotopic tumor is already highly vascularized and the cancer cells have begun to migrate out of the tumor. In contrast, the subcutaneous tumor only begins to be vascularized by day-3 and cells do not migrate from the tumor. Angiogenesis is much more extensive in the orthotopic tumor throughout the 2-week observation period. The orthotopic PC-3-GFP tumor progresses very rapidly and distinct metastasis have appeared in lymph nodes by day-3 which rapidly appear in many areas of the abdominal cavity including portal lymph nodes by day-7. At day-14, no invasion or metastasis was observed with the s.c. tumor even when the animal was extensively explored. These results explain why orthotopic tumors mimimc clinical metastatic tumors in nude mice and why subcutaneous tumors do not. J. Cell. Biochem. 117: 2546-2551, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  ANGIOGENESIS; GFP IMAGING; INTRAVITAL; INVASION; METASTASIS; ORTHOTOPIC; PC-3; PROSTATE CANCER; SUBCUTANEOUS

Mesh:

Substances:

Year:  2016        PMID: 27012365     DOI: 10.1002/jcb.25547

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

1.  [Establishment of mouse model of bone metastasis of prostate cancer and breast cancer via femoral artery injection of tumor cells].

Authors:  Zhao-Yang Yin; Si-Yong Qi; Xiang Cheng; Liang Guo; Hong-Yu Chen; Ming Shi
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

2.  Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection.

Authors:  Hye Jin Lee; Emily B Ehlerding; Dawei Jiang; Todd E Barnhart; Tianye Cao; Weijun Wei; Carolina A Ferreira; Peng Huang; Jonathan W Engle; Weibo Cai
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

3.  Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Takashi Murakami; Shinji Miwa; Scott D Nelson; Sarah M Dry; Yunfeng Li; Arun Singh; Hiroaki Kimura; Katsuhiro Hayashi; Norio Yamamoto; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2016-11-10       Impact factor: 4.534

4.  Effects of dietary omega-3 fatty acids on orthotopic prostate cancer progression, tumor associated macrophages, angiogenesis and T-cell activation-dependence on GPR120.

Authors:  Pei Liang; Susanne M Henning; Tristan Grogan; David Elashoff; Huihui Ye; Pinchas Cohen; William J Aronson
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-24       Impact factor: 5.455

5.  Difference in morphology and interactome profiles between orthotopic and subcutaneous gastric cancer xenograft models.

Authors:  Kiyotaka Nakano; Takashi Nishizawa; Daisuke Komura; Etsuko Fujii; Makoto Monnai; Atsuhiko Kato; Shin-Ichi Funahashi; Shumpei Ishikawa; Masami Suzuki
Journal:  J Toxicol Pathol       Date:  2018-08-13       Impact factor: 1.628

Review 6.  Uncoupling Traditional Functionalities of Metastasis: The Parting of Ways with Real-Time Assays.

Authors:  Sagar S Varankar; Sharmila A Bapat
Journal:  J Clin Med       Date:  2019-06-28       Impact factor: 4.241

7.  Pharmacokinetic-Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells.

Authors:  Shen Cheng; Susheel Kumar Nethi; Mahmoud Al-Kofahi; Swayam Prabha
Journal:  Pharmaceutics       Date:  2021-01-12       Impact factor: 6.321

Review 8.  Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.

Authors:  Nicolae Ghinea
Journal:  Diseases       Date:  2021-04-10

9.  Noninvasive Anatomical and Functional Imaging of Orthotopic Glioblastoma Development and Therapy using Multispectral Optoacoustic Tomography.

Authors:  Ghayathri Balasundaram; Lu Ding; Xiuting Li; Amalina Binte Ebrahim Attia; Xose Luis Dean-Ben; Chris Jun Hui Ho; Prashant Chandrasekharan; Hui Chien Tay; Hann Qian Lim; Chee Bing Ong; Ralph P Mason; Daniel Razansky; Malini Olivo
Journal:  Transl Oncol       Date:  2018-08-11       Impact factor: 4.243

10.  Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Authors:  Nada M S Al-Saffar; Helen Troy; Anne-Christine Wong Te Fong; Roberta Paravati; L Elizabeth Jackson; Sharon Gowan; Jessica K R Boult; Simon P Robinson; Suzanne A Eccles; Timothy A Yap; Martin O Leach; Yuen-Li Chung
Journal:  Br J Cancer       Date:  2018-10-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.